<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206931</url>
  </required_header>
  <id_info>
    <org_study_id>21002</org_study_id>
    <nct_id>NCT03206931</nct_id>
  </id_info>
  <brief_title>Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion</brief_title>
  <official_title>Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      Selitrectinib expanded access is for minor and adult patients with cancer having a change in
      a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an
      ongoing selitrectinib clinical trial or have other considerations that prevent access to
      selitrectinib through an existing clinical trial. Expanded access is intended to treat
      individual patients with different types of cancers with a NTRK gene fusion, including blood
      cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Solid Tumors Harboring NTRK Fusion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selitrectinib (BAY2731954)</intervention_name>
    <description>Selitrectinib is administered as capsules or liquid formulation.</description>
    <other_name>Loxo-195</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion

          -  Previous treatment with a kinase inhibitor with known activity on TRK inhibition

          -  Unable to participate in an ongoing selitrectinib clinical trial

          -  Medically suitable for treatment with selitrectinib

        Exclusion Criteria:

          -  Currently enrolled in an ongoing clinical study with a TRK inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Neurotrophic tyrosine receptor kinase (NTRK)</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>Fusion Positive</keyword>
  <keyword>Children</keyword>
  <keyword>Loxo-195</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>9-Fluoro-15-methyl-2,11,16,20,21,24-hexaazapentacyclo(16.5.2.02,6.07,12.021,25)pentacosa-1(24),7,9,11,18(25),19,22-heptaen-17-one</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

